Market Research Logo

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

Summary

GlobalData's clinical trial report, “Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019 provides an overview of Diffuse Large B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2019*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
      • Table Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
      • Table Figure 3: Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
      • Table Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
        • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
        • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
        • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
        • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
        • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
  • Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
    • Table Figure 9: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2019*
    • Table Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2019*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
    • Table Figure 12: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2019*
    • Table Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2019*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by Phase
    • Table Figure 15: Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2019*
    • In Progress Trials by Phase
      • Table Figure 16: Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
      • Table Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Clinical Trials by Trial Status
    • Table Figure 17: Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by End Point Status
    • Table Figure 18: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
    • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
  • Prominent Sponsors
    • Table Figure 21: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
    • Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials
      • Table Figure 22: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
      • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Prominent Drugs
    • Table Figure 23: Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
    • Table Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma
    • May 08, 2019: Innovative Cellular Therapeutics announces data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
    • May 07, 2019: Two clinical studies with IBI301, a biosimilar candidate to rituximab, met primary endpoints
    • May 03, 2019: IMV to provide updated data from phase 2 study evaluating DPX-Survivac in combination with Merck's Keytruda in DLBCL
    • May 01, 2019: Mixed results for new lymphoma therapy
    • Apr 10, 2019: Nordic Nanovector: safety review committee approves advancing to final dosing regimen in phase 1 trial of Betalutin in DLBCL
    • Apr 10, 2019: First patient enrolled in clinical trial for TREAKISYM rapid infusion liquid formulation
    • Apr 08, 2019: Completion of patient enrollment in phase 3 clinical trial of the anti-cancer drug Treakisym in relapsed/refractory diffuse large B-cell lymphoma
    • Apr 02, 2019: Kura Oncology identifies farnesylated proteins associated with CXCL12 expression, potential biomarker of clinical benefit from Tipifarnib in lymphoma indications
    • Mar 29, 2019: Kymera Therapeutics to present new preclinical data for its first-in-class oral IRAK4 degrader in MYD88-mutant lymphoma at late-breaking session of the American Association for Cancer Research Annual Meeting
    • Mar 28, 2019: Molecular Templates announces initiation of phase II monotherapy study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients
    • Mar 07, 2019: MorphoSys provides updates on L-MIND and B-MIND clinical trials of MOR208 in relapsed/refractory DLBCL
    • Mar 05, 2019: EMA recommends Phase III study for VAL001
    • Feb 20, 2019: ADC Therapeutics announces first patient dosed in phase I clinical trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report